Inclusion Criteria:

1. Age 18 or older

2. Biopsy proven progressive, recurrent (post-surgical, radiation therapy, chemotherapy,
combination therapy),or metastatic SCC of the head and neck which, in the judgment of
the attending physician, is incurable by standard treatment modalities, OR Biopsy
proven SCC which the patient is unwilling to have treated with surgery, chemotherapy
or radiation therapy

3. One or more of the following: -MAGE-A3 positive tumor -HPV 16 positive tumor.

4. Laboratory values obtained less than or equal to 30days prior to registration:
-Alkaline phosphatase less than or equal to 3x upper normal limit (UNL) -AST less
than or equal to 3x UNL -Creatinine less than or equal to 1.5 x UNL -Hemoglobin
greater than or equal to 9.0 g/dL -Albumin greater than or equal to 3 mg/dL

5. The subject must be capable of understanding the investigational nature, potential
risks and benefits of the study and capable of providing valid informed consent.

6. The subject must be willing to return to the University of Maryland Medical center
for treatment and study related follow up procedures including blood and tumor
collections and completion of imaging studies as required by the protocol.

7. ECOG performance status 0-2.

8. Tumor that is biopsy accessible and measurable. This includes, but is not limited to,
open biopsy, endoscopic biopsy, image guided biopsy, core biopsy and fine needle
aspiration.

EXCLUSION

1. Any of the following:

a. Known HIV infection, b. Other circumstances (i.e. concurrent use of systemic
immunosuppressants and immunocompromising condition) that in the opinion of the
physician renders the patient a poor candidate for this trial. c. Patients with ANY
malignant or metastatic SCC mass or lesion within the Central Nervous System (CNS).
(e.g. Intraparenchymal/ Brain, Intracordal / Spinal Canal, Bony masses or lesions
with extension into the CNS parenchyma) d. Patients with ANY malignant or metastatic
SCC mass or lesion or a volume of a mass or lesion in a location that in the judgment
of the investigator may significantly impair the health of or threaten the patients
life, should an Inflammatory Response occur.

2. Any of the following prior therapies: Chemotherapy less than or equal to 4 weeks
prior to registration Immunotherapy less than or equal to 4 weeks prior to
registration Biologic therapy less than or equal to 4 weeks prior to registration
Radiation therapy less than or equal to 4 weeks prior to registration

3. Any of the following: Pregnant women Nursing women unwilling to stop breastfeeding
Men or women of childbearing potential who are unwilling to employ adequate
contraception (condoms, diaphragm, birth control pills, injections, intrauterine
device [IUD], or abstinence, etc.) NOTE:This study involves an investigational agent
whose genotoxic, mutagenic and teratogenic effects on the developing fetus and
newborn are unknown.

4. Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational (utilized for a non-FDA-approved indication and in the
context of a research investigation).

5. Either of the following: Other active cancer requiring therapy to control the disease
History of other malignancy (i.e. excluding disease under study) within 3 years
Exceptions to the above include: adequately treated basal cell or squamous cell skin
cancer, prostate cancer.